ASCO: Pfizer Scores in Lung, Colorectal and Prostate Cancer but Key Readouts Still to Come

Why It Matters

The results strengthen Pfizer’s position in three high‑growth cancer markets and help offset the looming Ibrance patent cliff, while the Innovent alliance expands its global pipeline. Investors see these data as a catalyst for future revenue and a hedge against upcoming generic competition.

Key Takeaways

• Lobrena cut progression risk 81% in ALK‑positive NSCLC over seven years
• Braftovi + FOLFIRI halved progression risk, PFS 15.2 months in colorectal cancer
• Talzenna + Xtandi reduced radiographic progression 52% in metastatic prostate cancer
• Atirmociclib achieved 88% cell‑cycle arrest, but 20% patients reported diarrhea
• SSGJ‑707 bispecific antibody showed 75% ORR in squamous NSCLC

Pulse Analysis

Pfizer’s aggressive oncology push at ASCO 2026 underscores a strategic pivot toward diversified, globally sourced assets. The $10.5 billion Innovent collaboration not only supplies a pipeline of antibody‑based candidates but also signals Pfizer’s intent to capture market share in China’s fast‑growing cancer therapeutics sector. By pairing its internal R&D with external innovation, Pfizer aims to replenish the revenue stream that will be eroded when Ibrance loses exclusivity next year, a move that could otherwise create a sizable sales gap.

The conference data deliver tangible commercial upside. Lobrena’s seven‑year follow‑up, showing an 81% drop in progression or death, positions it as a potential new standard of care for first‑line ALK‑positive NSCLC, a market worth billions of dollars. Similarly, the Braftovi + FOLFIRI regimen more than doubled progression‑free survival in BRAF‑mutant colorectal cancer, offering a differentiated option that could capture a sizable slice of the $5‑6 billion colorectal market. In prostate cancer, the Talzenna‑Xtandi combination’s 52% risk reduction may extend the life of Xtandi’s brand value as generics loom, preserving cash flow for Pfizer’s broader oncology portfolio.

Looking ahead, Pfizer’s pipeline is designed to mitigate upcoming patent cliffs and sustain growth. Atirmociclib, the Ibrance heir, shows promising biomarker activity but raises tolerability questions that will shape its regulatory path. The bispecific PD‑1/VEGF antibody SSGJ‑707 delivered high response rates in NSCLC, hinting at a next‑generation immunotherapy platform. With multiple late‑stage readouts scheduled for mid‑ to late‑2026—including an ADC versus docetaxel and an EZH2 inhibitor in prostate cancer—Pfizer is betting on a wave of data to keep its oncology franchise robust and investor confidence high.